A UTHealth Houston team will randomize 100 people on semaglutide to stop or continue treatment and look for genetic and molecular markers that may explain weight regain.
Medical Xpress, carrying a HealthDay report, covers a UK national prospective observational cohort study in Anaesthesia of 47,039 adults at 119 sites undergoing anesthesia. Of these, 2.9% reported taking GLP-1 receptor agonists. Pulmonary aspiration and/or regurgitation occurred in 1.41% of that group versus 0.12% of others (odds ratio, 11.39), most often during emergence from anesthesia. Perioperative management varied, and the authors call for further prospective studies.
Our summary →ScienceAlert reports on a phase 3 trial in The New England Journal of Medicine of retatrutide, an experimental weekly injection, in 2,339 adults with obesity but without diabetes. At 12 milligrams, average weight loss was 25 percent after 80 weeks versus 3.9 percent with placebo; knee pain and sleep apnea events also fell more. Nausea was common. Eli Lilly funded the study, which did not compare it with existing drugs.
Our summary →CNBC reports that Eli Lilly and Novo are developing amylin-targeting obesity drugs to complement GLP-1 medicines. In a relatively small Phase 2 trial in patients with obesity and Type 2 diabetes, the highest-dose combination of Lilly's experimental eloralintide with tirzepatide produced 23.3% average weight loss at 48 weeks versus 14.8% on high-dose tirzepatide alone, though 10.8% to 27% stopped due to side effects. Phase 3 trials are needed.
Our summary →Newsweek reports on a cross-sectional, self-reported study presented at EADV in Vienna comparing 575 GLP-1 receptor users with 1,329 people with Type 2 diabetes who had never taken the drugs. Nail detachment was reported by 39 percent of users versus 9 percent of controls, and hair loss by 50 percent of users. Associations weakened after adjusting for skin conditions and nutritional deficiencies; authors say causation cannot be inferred.
Our summary →News-Medical reports on a retrospective, real-world study of 122 adults with overweight or obesity, without type 2 diabetes, treated at two centers in Palermo, Italy. Alongside diet and activity advice, 24 weeks of tirzepatide was associated with fat mass falling 35.4% while skeletal muscle mass stayed stable. There was no control arm, and most participants were women.
Our summary →Healio reports on a congress presentation of an observational study comparing 575 GLP-1 receptor agonist users with 1,329 non-users, all with type 2 diabetes and/or obesity. Users reported more nail disorders and hair loss, including nail detachment (39.3% vs. 8.7%) and new-onset hair loss (26.1% vs. 11.6%). Researchers say the design cannot establish that the drugs caused the changes; a prospective study is planned.
Our summary →AthleticsMD
ShredRx is AthleticsMD's physician-guided medical weight-loss program in Columbia and Laurel/Fort Meade, Maryland.